NDNatalia Dziewa

Natalia Dziewa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia Dziewa has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Proctological patient with von Willebrand’s disease as a surgical challenge – presentation of two cases

    by Radosław Cylke, Antonina Respondek-Bartuś, Małgorzata Kołodziejczak, Natalia Dziewa

    Von Willebrand disease is the most common inherited bleeding disorder (0.6-1.3% of the general population). A proctological patient with von Willebrand disease poses a particular surgical challenge, as the procedures performed in these patients are associated with an increased risk of haemorrhage. The purpose of this paper was to present two cases of anorectal patients with co-existing von Willebrand’s disease, as well as to summarise the literature review on the perioperative management of such patients. Based on the literature review, it can be concluded that adequate preoperative care reduces the risk of major bleeding close to the one seen the general population. The risk of bleeding can be minimised by careful perioperative haemostasis and substitution treatment. Both FVIII/VWF clotting factor concentrates (CFCs) and desmopressin (DDAVP) are effective and safe in preventing bleeding during surgery or invasive procedures in patients with von Willebrand’s disease. Treatment strategies vary depending on disease severity, surgical extent, the intensity and nature of bleeding in a given patient, as well as the treatment used and the time of its administration. There is no clear consensus among clinicians on standardised guidelines for the management of patients with von Willebrand’s disease who are scheduled for surgical treatment.

  • Open Access

    Development and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients

    by Magdalena Bodnar-Broniarczyk, Karola Warzyszyńska, Katarzyna Czerwińska, Dorota Marszałek, Natalia Dziewa, Maciej Kosieradzki, Tomasz Pawiński

    (1) Background: Only unbound tacrolimus particles are considered to be active and capable of crossing cellular membranes. Thus, the free-drug concentration might be better associated with clinical effects than the total drug concentration used for dosage adjustment. We propose a new, fully validated online liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for unbound tacrolimus concentration measurement. (2) Methods: The determination of the unbound tacrolimus concentration in plasma ultrafiltrate was performed with the Nexera LC system with LCMS-8050 triple quadrupole MS using ascomycin as an internal standard. Chromatographic separation was made using a HypurityC18 analytical column. MS/MS with electrospray ionization and positive-ion multiple-reaction monitoring was used. The unbound tacrolimus level was determined in 36 patients after solid organ transplantation (n = 140). (3) Results: A lower limit of quantification 0.1 pg/mL was achieved, and the assay was linear between 0.1 and 20 pg/mL (R2 = 0.991). No carry-over was detected. The within-run and between-run accuracies ranged between 97.8–109.7% and 98.3–107.1%, while the greatest imprecision was 10.6% and 10.7%, respectively. Free tacrolimus in patients’ plasma ultrafiltrate varied between 0.06 and 18.25 pg/mL (median: 0.98 pg/mL). (4) Conclusions: The proposed method can be easily implemented. The significance of the unbound tacrolimus concentration needs to be investigated. This may facilitate the individualization and optimization of immunosuppressive treatment.